![]() |
市場調査レポート
商品コード
1576516
止血剤の市場規模、シェア、予測、動向分析:タイプ別・用途別・エンドユーザー別 - 2031年までの世界の予測Hemostats Market Size, Share, Forecast, & Trends Analysis by Type Form Application End User - Global Forecast to 2031 |
||||||
カスタマイズ可能
|
止血剤の市場規模、シェア、予測、動向分析:タイプ別・用途別・エンドユーザー別 - 2031年までの世界の予測 |
出版日: 2024年08月01日
発行: Meticulous Research
ページ情報: 英文 280 Pages
納期: 5~7営業日
|
止血剤市場は、2024年から2031年にかけてCAGR 6.9%で2031年までに53億2,000万米ドルに達すると予測されます。
本レポートは、広範な2次調査と1次調査、市場シナリオの詳細な分析を経て、主要な市場促進要因、抑制要因、課題、機会の分析から構成されています。この市場の成長は、がん、心血管疾患、整形外科疾患、神経疾患などの慢性疾患の有病率の上昇とそれに伴う外科手術量の増加、事故率の上昇、帝王切開分娩数の増加、致命的な怪我、臓器移植、研究開発活動の増加、医療費の増加、低侵襲外科手術への嗜好の高まりなどに起因しています。しかし、止血剤に使用される材料によるアレルギー反応がこの市場の成長を抑制しています。
さらに、高度な止血剤の使用の増加、歯科用止血剤の進歩、装填済み塗布器やRTU止血剤の需要の増加は、この市場で事業を展開する企業に成長機会をもたらすと期待されています。しかし、止血剤の製造コストが高いことや、高度な抗菌止血剤のコストが高いことが、市場成長に影響を与える大きな課題です。
(注:上位5社のSWOT分析を掲載)
Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User- Global Forecast to 2031
The hemostat market is projected to reach $5.32 billion by 2031 at a CAGR of 6.9% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. However, allergic reactions caused by the material used in making hemostats restrain the growth of this market.
Furthermore, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to generate growth opportunities for the players operating in this market. However, the high manufacturing cost for hemostasis and the high cost of advanced antimicrobial hemostatic agents are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the hemostat market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.).
Among all the types studied in this report, in 2024, the absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostat market. The segment's large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.
Among all the applications studied in this report, in 2024, the surgery segment is expected to account for the larger share of the hemostat market. The largest market share of this segment is attributed to the increasing number of surgeries, rise in the number of accidents, and growing demand for cosmetic/plastic surgeries. For instance, according to the World Health Organization (WHO), in 2021, yearly, 4.4 million people died from injuries, 3.16 million died from accidental wounds, and 1.25 million died from violence-related injuries globally.
Among all the forms studied in this report, in 2024, the matrix and gel segment is expected to account for the largest share of the hemostat market. The segment's large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.
Among all the end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostat market. The growing number of surgeries conducted in hospitals, the use of hemostats for control of minor, moderate, and severe bleeding in operating rooms, the availability of different forms of hemostats used for surgical procedures, and the availability of favorable reimbursement policies are some of the major factors driving the growth of this segment.
An in-depth analysis of the geographical scenario of the hemostat market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 32.9% of the hemostat market. In the region in 2024, the U.S. is expected to account for the largest share of the hemostat market in North America. The large share of this regional market is attributed to the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.
Hemostat Market Assessment-by Type
Hemostat Market Assessment-by Application
Hemostat Market Assessment-by Form
Hemostat Market Assessment-by End User
Hemostat Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)